The aggressive warrant coverage (39.6M warrants vs 1.6M shares) signals distressed financing. Expect downward pressure from dilution overhang. Monitor for stockholder approval vote and subsequent registration of resale shares. The stock may trade toward the offering price of $2.65 or below as the market absorbs the private placement terms.
Price Chart
Executive Summary
Cellectar Biosciences is conducting a dilutive public offering of 1.6M shares at $2.65 (6.4% discount to last close) alongside a massive private placement including 2.1M shares, 9.5M prefunded warrants, and 39.6M common warrants. Net proceeds of ~$3.9M will fund working capital and a Phase 3 trial, but the company explicitly states existing cash is insufficient for its regulatory strategy. The enormous warrant coverage creates severe dilution overhang for existing shareholders.
Key Facts
- Public offering of 1,618,053 shares at $2.65, net proceeds ~$3.9M
- Concurrent private placement includes 2,116,887 shares, 9,471,086 prefunded warrants, and 39,618,078 common warrants (all at $2.65 exercise price)
- Lead investor Nantahala Capital gets board designation rights
- Management participated at $2.88 per share in the private placement
- Immediate dilution of $0.53 per share for new investors in the public offering
- Company states existing cash is not sufficient to execute regulatory strategy
Financial Impact
Public offering raises ~$3.9M net; private placement could add significant additional capital but with massive dilution. Total potential shares from private placement exceed 51M vs ~4.2M currently outstanding.
Risk Factors
- Severe dilution from full exercise of common warrants (39.6M shares)
- Going concern risk: company admits cash insufficient for regulatory strategy
- Regulatory approval uncertainty for iopofosine I 131
- Potential inability to raise additional funds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-056031 |
| Document: 0001104659-26-056031-index-headers.html | 0001104659-26-056031 |
| Document: 0001104659-26-056031-index.html | 0001104659-26-056031 |
| Document: 0001104659-26-056031.txt | 0001104659-26-056031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers